Safety and Efficacy of Prophylactic Amiodarone in Preventing Early Junctional Ectopic Tachycardia (JET) in Children After Cardiac Surgery and Determination of Its Risk Factor

2016 ◽  
Vol 37 (4) ◽  
pp. 734-739 ◽  
Author(s):  
Doaa El Amrousy ◽  
Walid Elshehaby ◽  
Wael El Feky ◽  
Nagat S. Elshmaa
2005 ◽  
Vol 53 (S 01) ◽  
Author(s):  
G Szabó ◽  
P Soós ◽  
L Seres ◽  
S Hagl

2008 ◽  
Vol 56 (S 1) ◽  
Author(s):  
A Kowalski ◽  
F Schoeneich ◽  
M Ernst ◽  
N Haake ◽  
J Cremer

2018 ◽  
Vol 69 (4) ◽  
pp. 875-880
Author(s):  
Oana Roxana Chivu ◽  
Ovidiu Mederle ◽  
Augustin Semenescu ◽  
Ileana Mates ◽  
Claudiu Babis ◽  
...  

The paper describes how to determine the noise in a production hall where there are production machines and equipment. The chosen plant is a production unit where filling of the polyurethane foam tubes is performed. The main activity is the production of professional insulators and wholesale of other products from the same range enumerating the following: wholesale chemical products; production of professional insulators; trade in chemicals and chemical industry. The recommended maximum admissible value for a normal 8h work program is 85 dB (A). The objective is to determine the level of noise in the factory and how it acts as a physical professional risk factor and its effects on the human body. The way in which the proposed objective was achieved was to determine the value of the noise level with the specialized equipment. Following the determinations that will be presented in the following chapters, appropriate protective measures have been taken.


Neonatology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Kasia Trzcionkowska ◽  
Floris Groenendaal ◽  
Peter Andriessen ◽  
Peter H. Dijk ◽  
Frank A.M. van den Dungen ◽  
...  

<b><i>Introduction:</i></b> Retinopathy of prematurity (ROP) remains an important cause for preventable blindness. Aside from gestational age (GA) and birth weight, risk factor assessment can be important for determination of infants at risk of (severe) ROP. <b><i>Methods:</i></b> Prospective, multivariable risk-analysis study (NEDROP-2) was conducted, including all infants born in 2017 in the Netherlands considered eligible for ROP screening by pediatricians. Ophthalmologists provided data of screened infants, which were combined with risk factors from the national perinatal database (Perined). Clinical data and potential risk factors were compared to the first national ROP inventory (NEDROP-1, 2009). During the second period, more strict risk factor-based screening inclusion criteria were applied. <b><i>Results:</i></b> Of 1,287 eligible infants, 933 (72.5%) were screened for ROP and matched with the Perined data. Any ROP was found in 264 infants (28.3% of screened population, 2009: 21.9%) and severe ROP (sROP) (stage ≥3) in 41 infants (4.4%, 2009: 2.1%). The risk for any ROP is decreased with a higher GA (odds ratio [OR] 0.59 and 95% confidence interval [CI] 0.54–0.66) and increased for small for GA (SGA) (1.73, 1.11–2.62), mechanical ventilation &#x3e;7 days (2.13, 1.35–3.37) and postnatal corticosteroids (2.57, 1.44–4.66). For sROP, significant factors were GA (OR 0.37 and CI 0.27–0.50), SGA (OR 5.65 and CI 2.17–14.92), postnatal corticosteroids (OR 3.81 and CI 1.72–8.40), and perforated necrotizing enterocolitis (OR 7.55 and CI 2.29–24.48). <b><i>Conclusion:</i></b> In the Netherlands, sROP was diagnosed more frequently since 2009. No new risk factors for ROP were determined in the present study, apart from those already included in the current screening guideline.


Phlebologie ◽  
2015 ◽  
Vol 44 (06) ◽  
pp. 316-319 ◽  
Author(s):  
S. Harder

SummaryAnticoagulants are widely used for prophylaxis and treatment of venous thromboembolism in the elderly, who commonly have renal impairment and other comorbidities. Renal impairment is a risk factor for bleeding and thrombosis during anticoagulant therapy and can influence the balance between the safety and efficacy of such agents. Some anticoagulants, such as fondaparinux and the direct acting oral thrombin inhibitor dabigatran etexilate are contraindicated for use in patients with severe renal impairment (eGFR <30 ml/min). However, also the direct acting oral FXa-inhibitors rivaroxaban, edoxaban and apixaban need caution regarding dosing advice or contraindications when used in patients with renal impairment.


Sign in / Sign up

Export Citation Format

Share Document